BGM0504 vs RAY1225

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

BGM0504

Developed by BrightGene Bio-Medical Technology and partners

Phase 3 in Obesitypeptide
Partial signal

NCT06973681 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial enrolled 120 adults with overweight or obesity across three weekly BGM0504 doses and placebo. The primary endpoint was percentage change in body weight from baseline to week 24. A company announcement reported placebo-adjusted mean weight reductions of 10.77% to 19.78% across the BGM0504 dose groups, meeting the primary endpoint. No power calculation or planned enrolment was available to show the trial was adequately powered, and the result is not posted on ClinicalTrials.gov.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07658560 (registry estimate)

Reported efficacy

Percentage change in body weight (Week 0 to Week 24): Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) (met)

Result source: NCT06973681

RAY1225

Developed by Guangdong Raynovent Biotech and partners

Phase 3 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBGM0504RAY1225
Body weight, % change—Not posted · NCT06704581—Trial running · NCT06893016
Weight loss of 5% or more—Not posted · NCT06704581—Trial running · NCT06893016
Weight loss of 10% or more—Not posted · NCT06704581—Trial running · NCT06893016
Waist circumference, change (cm)—Not posted · NCT06704581—Trial running · NCT06893016

Body weight, % change

BGM0504
—Not posted · NCT06704581
RAY1225
—Trial running · NCT06893016

Weight loss of 5% or more

BGM0504
—Not posted · NCT06704581
RAY1225
—Trial running · NCT06893016

Weight loss of 10% or more

BGM0504
—Not posted · NCT06704581
RAY1225
—Trial running · NCT06893016

Waist circumference, change (cm)

BGM0504
—Not posted · NCT06704581
RAY1225
—Trial running · NCT06893016
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

RAY1225: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BGM0504
Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) NCT06973681 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM0504's landscape · RAY1225's landscape